SCHEDULE: Titan Trust 2024 I Discloses 5.32% Stake in DarioHealth Corp.
Beneficial Ownership Disclosure
Titan Trust 2024 I has disclosed a 5.32% beneficial ownership stake in DarioHealth Corp., primarily through warrants.
Summary
- Titan Trust 2024 I reported beneficial ownership of 2,500,100 shares of DarioHealth Corp. common stock.
- This represents 5.32% of the company's outstanding common stock.
- The ownership is primarily derived from shares issuable under a warrant dated February 15, 2024, which becomes exercisable within 60 days after June 9, 2025.
- The percentage was calculated based on 44,463,781 shares outstanding as of May 29, 2025, as reported in DarioHealth Corp.'s Proxy Statement filed on May 30, 2025, plus the 2,500,100 shares held by Titan Trust 2024 I.
- WhiteHawk Capital Partners LP acts as the administrator for Titan Trust 2024 I.
- The securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 7
Explanation: The disclosure of a new significant beneficial owner, especially an institutional trust, is generally viewed positively as it indicates investor interest and confidence, even if the stake is derived from warrants from a prior transaction.
Positives
- A new institutional investor, Titan Trust 2024 I, has taken a significant 5.32% stake in DarioHealth Corp., potentially signaling confidence in the company's future.
- The stake is primarily through warrants, indicating a prior investment decision that is now being disclosed as it crosses the 5% beneficial ownership threshold.
Future Outlook
The filing does not provide forward-looking statements or guidance regarding DarioHealth Corp.'s future operations or financial performance.
Industry Context
This filing is a standard disclosure of beneficial ownership and does not provide specific insights into broader industry trends or competitive landscape within the digital health or healthcare technology sector.
Stakeholder Impact
- Shareholders: The disclosure of a new significant investor could be perceived positively, potentially boosting investor confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-02-15 | Date of warrant issuance. |
| 2025-05-29 | Date for which 44,463,781 shares of Common Stock outstanding were reported in the Issuer's Proxy Statement. |
| 2025-05-30 | Date Issuer's Proxy Statement for Annual Meeting of Stockholders was filed with the SEC. |
| 2025-06-09 | Date of event which requires filing of this statement, and the date after which the warrant is exercisable within 60 days. |
| 2025-07-22 | Date of filing signature. |
Recommendation
holdThis Schedule 13G filing primarily serves as a disclosure of a significant beneficial ownership stake by Titan Trust 2024 I in DarioHealth Corp., largely through warrants. While the emergence of a new institutional investor can be a positive signal, the filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It confirms a pre-existing investment structure (warrants from February 2024) that has now crossed the 5% disclosure threshold. Investors should 'hold' and await further operational updates or financial results from DarioHealth Corp. to make a more informed investment decision.
Keywords
DarioHealth Corp., Titan Trust 2024 I, WhiteHawk Capital Partners, Beneficial Ownership, Schedule 13G, Common Stock, Warrant, Healthcare Technology, Digital Health
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.